Antiviral Agents Against COVID-19 Infection

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

August 4, 2021

Study Completion Date

August 4, 2021

Conditions
COVID-19
Interventions
DRUG

Atazanavir

600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.

DRUG

Daclatasvir 60 mg

initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.

DRUG

Sofusbuvir + Daclastavir 60 mg

400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofusbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)

DRUG

Placebo Atazanavir

2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.

DRUG

Placebo Daclatasvir 60 mg

2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.

DRUG

Placebo Sofusbuvir + Daclatasvir 60 mg

2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.

Trial Locations (1)

04005-000

Hospital do Coracao, São Paulo

All Listed Sponsors
lead

Hospital do Coracao

OTHER

NCT04468087 - Antiviral Agents Against COVID-19 Infection | Biotech Hunter | Biotech Hunter